Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
| ▸ | KDM1A | O60341 | 3/20 | 0.32 |
| ▸ | ANPEP | P15144 | 3/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.31 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3459720 | 1.00 | CYP11B1 (0.38) | CYP11B1CYP11B2HTR2AHTR2CEPAS1 | |
| Hydrochloric Acid SCHEMBL8614165 | 0.98 | CYP11B1 (0.37) | CYP11B1CYP11B2HTR2AHTR2CEPAS1 | |
| SCHEMBL12501555 | 0.81 | CYP11B1 (0.36) | CYP11B1CYP11B2KDM1AANPEPKCNH2 | |
| SCHEMBL16290335 | 0.81 | CYP11B1 (0.36) | CYP11B1CYP11B2KDM1AANPEPKDM1B | |
| SCHEMBL31034383 | 0.81 | CYP11B1 (0.36) | CYP11B1CYP11B2KDM1AANPEPKCNH2 | |
| SCHEMBL16290385 | 0.81 | HTR2A (0.34) | CYP11B1CYP11B2HTR2AHTR2CEPAS1 | |
| SCHEMBL16290348 | 0.81 | CYP11B1 (0.33) | CYP11B1CYP11B2EPAS1KDM1AANPEP | |
| SCHEMBL23136253 | 0.76 | HTR2A (0.36) | HTR2AHTR2C | |
| SCHEMBL326748 | 0.76 | CYP11B1 (0.38) | CYP11B1CYP11B2HTR2AHTR2CEPAS1 | |
| SCHEMBL1150762 | 0.72 | DRD2 (0.49) | CYP11B1CYP11B2HTR2CANPEPDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795166-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2023-10-24 | — | — | US | disclosed |
| EP-4119558-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | Incyte Corporation (US) | 2023-01-18 | — | — | EP | disclosed |
| US-11542265-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2023-01-03 | — | — | US | disclosed |
| CN-109923114-B | Pyrazolopyridine derivatives as HPK1 modulators and their use for the treatment of cancer | 因赛特公司 | 2022-11-01 | — | — | CN | disclosed |
| EP-3510032-B1 | PYRAZOLOPYRIDINE DERIVATIVES AS HPK1 MODULATORS AND USES THEREOF FOR THE TREATMENT OF CANCER | INCYTE CORP (US) | 2022-07-06 | — | — | EP | disclosed |
| US-20210380581-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2021-12-09 | — | — | US | disclosed |
| US-20210371425-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2021-12-02 | — | — | US | disclosed |
| US-11014929-B2 | Pyrazolopyrimidine compounds and uses thereof | INCYTE CORPORATION (US) | 2021-05-25 | — | — | US | disclosed |
| US-10934288-B2 | Pyrazolopyridine compounds and uses thereof | INCYTE CORPORATION (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200172545-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2020-06-04 | — | — | US | disclosed |
| EP-3107900-B1 | 5-BENZYLISOQUINOLEINE DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | SERVIER LAB (FR) | 2017-11-15 | — | — | EP | disclosed |
| US-9809553-B2 | Isoquinoline compounds, a process for their preparation, and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2017-11-07 | — | — | US | disclosed |
| US-9809553-B2 | Isoquinoline compounds, a process for their preparation, and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2017-11-07 | — | — | US | disclosed |
| US-20170137385-A1 | ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2017-05-18 | — | — | US | disclosed |
| US-20170137385-A1 | ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LES LABORATOIRES SERVIER (FR) | 2017-05-18 | — | — | US | disclosed |
| WO-2015124877-A1 | DERIVATIVES OF 5-BENZYLISOQUINOLINE FOR THE TREATMENT OF CARDIOVASCULAR DISEASES | LES LABORATOIRES SERVIER (FR) | 2015-08-27 | — | — | WO | disclosed |
| US-5719280-A | REACTING AMINE SUBSTITUTED BENZOCYCLOALKANE WITH DIALKYLOXYACETALDEHYDE IN PRESENCE OF REDUCING AGENT OR CATALYTIC HYDROGENATION, TREATING WITH THIOCYANIC ACID | SYNTEX (U.S.A.) INC. (US) | 1998-02-17 | — | — | US | disclosed |
| EP-0757677-A1 | BENZOCYCLOALKYLAZOLETHIONE DERIVATIVES | SYNTEX (U.S.A.) INC. (US) | 1997-02-12 | — | — | EP | disclosed |
| US-5538988-A | CARDIOVASCULAR DISORDERS AND DOPAMINE HYDROLASE ENZYME INHIBITORS | SYNTEX (U.S.A.) INC. | 1996-07-23 | — | — | US | disclosed |
| WO-1995029165-A2 | BENZOCYCLOALKYLAZ0LETHIONE DERIVATIVES AS DOPAMIN BETA-HYDROXYLASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1995-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172545-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, MAPKAPK5 | CYP11B1 780/4885CYP11B2 779/4885HTR2A 4342/4885 |
| US-11795166-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | CYP11B1 779/4885CYP11B2 705/4885HTR2A 3665/4885 |
| US-10934288-B2 | Pyrazolopyridine compounds and uses thereof | PDXK, PCK1, PGK1 | CYP11B1 779/4885CYP11B2 705/4885HTR2A 3665/4885 |
| US-11014929-B2 | Pyrazolopyrimidine compounds and uses thereof | PDXK, PCK1, MAPKAPK5 | CYP11B1 780/4885CYP11B2 779/4885HTR2A 4342/4885 |
| US-20210380581-A1 | PYRAZOLOPYRIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PGK1 | CYP11B1 779/4885CYP11B2 705/4885HTR2A 3665/4885 |
| US-20170137385-A1 | ISOQUINOLINE COMPOUNDS, A PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MYLK, MYLK2, MYLK3 | CYP11B1 222/4885CYP11B2 152/4885HTR2A 2622/4885 |
| US-11542265-B2 | Pyrazolopyrimidine compounds and uses thereof | PDXK, PCK1, PDK2 | CYP11B1 822/4885CYP11B2 793/4885HTR2A 4094/4885 |
| US-20210371425-A1 | PYRAZOLOPYRIMIDINE COMPOUNDS AND USES THEREOF | PDXK, PCK1, PDK2 | CYP11B1 822/4885CYP11B2 793/4885HTR2A 4094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.